Movement Alert｜SBP GROUP Falls 3.05% in Regular Trading, Two Hepatitis B Drug Candidates Receive Breakthrough Therapy Designation

Market Focus10-27 13:25

On October 27, SBP GROUP fell 3.05% in Regular Trading, trading at HK$4.76, with turnover of HK$212 million.

The main disclosed catalyst was the company announcement that two chronic hepatitis B drug candidates developed by its subsidiary Chia Tai Tianqing, TQ-A3334 and TQA3605, were included in the breakthrough therapy program by China’s drug evaluation authority.

According to the company filing, TQ-A3334 is an oral TLR7 agonist aimed at achieving a functional cure and is preparing to enter Phase III clinical trials, while TQA3605 is a core protein allosteric modulator targeting patients with persistently low viral levels despite treatment and has already entered Phase III. The update highlights continued progress in SBP GROUP’s hepatitis B innovation pipeline, although the share price moved lower alongside weakness across pharmaceutical names on the day.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment